Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A.

K M Krajewski1, R A Lewis, D R Fuerst

  • 1Department of Neurology, Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.

Brain : a Journal of Neurology
|June 27, 2000
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-reported disease burden in the Accelerate Clinical Trials in Charcot-Marie-Tooth Disease Study.

Journal of the peripheral nervous system : JPNS·2024
Same author

The integrated stress response contributes to tRNA synthetase-associated peripheral neuropathy.

Science (New York, N.Y.)·2021
Same author

Are we prepared for clinical trials in Charcot-Marie-Tooth disease?

Brain research·2020
Same author

Transcranial direct current stimulation (tDCS) for the treatment of a Multiple Sclerosis symptom cluster.

Brain stimulation·2019
Same author

Mutation update for myelin protein zero-related neuropathies and the increasing role of variants causing a late-onset phenotype.

Journal of neurology·2019
Same author

Increased thalamic activity and less neuropathic pain after tDCS observed with PET in a patient with multiple sclerosis: A case report.

Brain stimulation·2018

Charcot-Marie-Tooth disease type 1A (CMT1A) involves nerve axon damage. Muscle weakness and sensory loss correlate with disability, suggesting treatments should focus on preventing axon degeneration for CMT1A patients.

Area of Science:

  • Neurology
  • Genetics
  • Neuroscience

Background:

  • Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form of CMT, caused by a specific chromosome 17 duplication.
  • CMT1A patients exhibit characteristic symptoms like slowed nerve conduction and distal limb weakness.

Purpose of the Study:

  • To investigate the molecular pathogenesis of CMT1A.
  • To identify clinical and electrophysiological features correlating with neurological dysfunction and potential treatment targets in CMT1A.

Main Methods:

  • Clinical and electrophysiological evaluation of 42 CMT1A patients.
  • Correlation analysis between neurological deficits and specific electrophysiological measures.

Main Results:

Related Experiment Videos

  • Muscle weakness, reduced compound motor action potential (CMAP) amplitudes, and motor unit number estimates correlated with clinical disability.
  • Loss of joint position sense and reduced sensory nerve action potential (SNAP) amplitudes also correlated with disability.
  • Motor and sensory nerve conduction velocities (NCVs) did not correlate with clinical disability.

    • Conclusions:

    • Neurological dysfunction and disability in CMT1A are likely due to the loss or damage of large-caliber motor and sensory axons.
    • Therapeutic strategies for CMT1A should aim to prevent axonal degeneration and promote axonal regeneration, similar to approaches for other neurodegenerative diseases.